NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The medical research company earned $104.70 million during the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The company's revenue was up 51.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.05 EPS. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

6 equities research analysts have issued 1 year price targets for NeoGenomics' shares. Their forecasts range from $14.00 to $30.00. On average, they expect NeoGenomics' stock price to reach $22.60 in the next twelve months. This suggests that the stock has a possible downside of 31.5%. View Analyst Price Targets for NeoGenomics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News stories about NEO stock have been trending negative on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NeoGenomics earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in December. As of December 31st, there was short interest totalling 6,920,000 shares, an increase of 9.1% from the December 15th total of 6,340,000 shares. Based on an average daily trading volume, of 678,300 shares, the days-to-cover ratio is currently 10.2 days. Currently, 7.0% of the shares of the stock are short sold. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include DENTSPLY SIRONA (XRAY), Alnylam Pharmaceuticals (ALNY), Steris (STE), GALAPAGOS NV/S (GLPG), Universal Health Services (UHS), Fisher & Paykel Healthcare (FPH), Insulet (PODD), West Pharmaceutical Services (WST), EXACT Sciences (EXAS), Elanco Animal Health (ELAN), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Mylan (MYL), Teva Pharmaceutical Industries (TEVA) and Canopy Growth (WEED).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Marvell Technology Group (MRVL), Micron Technology (MU), Netflix (NFLX), Amarin (AMRN), AbbVie (ABBV), Canopy Growth (CGC), CVS Health (CVS) and AT&T (T).

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.35%), Norris Perne & French LLP MI (0.33%), State of Alaska Department of Revenue (0.08%), Louisiana State Employees Retirement System (0.03%), HWG Holdings LP (0.01%) and Miles Capital Inc. (0.01%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Summit Creek Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was bought by a variety of institutional investors in the last quarter, including HWG Holdings LP, Miles Capital Inc., OLD National Bancorp IN, Sciencast Management LP, Norris Perne & French LLP MI, Exchange Traded Concepts LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $32.97.

NeoGenomics has a market capitalization of $3.44 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]